tbuckley/cabot-search huggingface dataset:
Altered Distribution of Technetium-99m Sodium Pertechnetate Associated with Antimicrobial Therapy
Authors: J J CASTRONUOVO, L R CHERVU, D M MILSTEIN
Journal: Clinical Nuclear Medicine (1985)

Three patients underwent brain scanning for evaluation of central nervous system disease and were simultaneously treated for infectious diseases unrelated to the central nervous process. All revealed intense vascular pooling on their brain images. The imaging studies had been performed following the administration of Tc-99m pertechnetate. None of the patients had prior nuclear medicine examinations to suggest the causal effect of stannous ion as a source of interference. All of the patients were on combination antimicrobial drugs: two on sulfamethoxazole and trimethoprim, and one on isoniazid and ethambutol. One patient revealed 75% Tc-99m red cell tagging. Another patient's repeat brain scan with Tc-99m DTPA revealed normal distribution. Our findings suggest that patients on antimicrobial combination drug regimens who require brain scans should be imaged routinely with agents other than Tc-99m.
Use of Polyethylene Glycol-Modified Uricase (PEG-Uricase) to Treat Hyperuricemia in a Patient with Non-Hodgkin Lymphoma
Authors: Cynthia C. Chua
Journal: Annals of Internal Medicine (1988)

Modification by covalent attachment of monomethoxypolyethylene glycol (PEG) can reduce the immunogenicity and prolong the circulating life of injected enzymes, making their use as therapeutic agents feasible. We report the first clinical use of PEG-modified Arthrobacter protoformiae uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma and renal insufficiency who was allergic to allopurinol. Two intramuscular injections totaling 3 U/kg body weight during the first 30 hours of treatment lowered the plasma urate level from 910 to 190 µmol/L (15.3 to 3.2 mg/dL), after which a dose of 2 U/kg every 5 to 6 days maintained the plasma urate level at 540 µmol/L (9 mg/ dL) or lower. After the injection of PEG-uricase, uricase activity appeared in plasma rapidly, peaking within 24 hours and persisting for approximately 5 days; an inverse relation between plasma uricase activity and plasma urate concentration was noted. The agent was nontoxic and well tolerated. No antibody to either PEG-uricase or unmodified uricase developed over a 3-week period, during which four doses of PEG-uricase were administered. Because of its long circulating life, PEG-uricase is probably a more effective hypouricemic agent than unmodified uricase, which has previously had limited use. As an adjunct to cytolytic therapy for hematologic malignancies when protection from hyperuricemia is needed rapidly, PEG-uricase deserves further study.
864-5 Effects of prolonged oral simvastatin treatment after coronary stenting on neointimal growth and plaque progression as assessed by intravascular ultrasound: A randomized study
Authors: Giovanni Amoroso, Anna Sonia Petronio, Barbara Papini, Andrea Micheli, Ugo Limbruno, Marco De Carlo, Nicola Ciabatti, Mario Mariani
Journal: Journal of the American College of Cardiology (2004)
Fatal All-Trans Retinoic Acid Pneumonitis
Authors: Raymond P. Warrell
Journal: Annals of Internal Medicine (1993)

Letters15 March 1993Fatal All-Trans Retinoic Acid PneumonitisRaymond P. Warrell Jr., MDRaymond P. Warrell Jr., MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-6-199303150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Smith-Whitley and Lange raise several important points. First, the “retinoic acid syndrome” is a constellation of clinical signs (fever, weight gain, pulmonary infiltrates, and pleural effusions) that can mimic various illnesses to which patients with acute promyelocytic leukemia (APL) are susceptible, especially congestive heart failure and infectious pneumonia [1]. (Indeed, our housestaff has identified two recent patients who presented with the “syndrome” before treatment was initiated.) Second, this complex by no means accounts for all idiosyncratic drug-related effects observed in patients with APL; variations have included pericarditis and high spiking fevers without an apparent infectious source, both of ...References1. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med. 1992; 117:292-6. Google Scholar2. Smith MA, Adamson PC, Balis FM, Feusner J, Aronson L, Murphy RF, et al. Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients with cancer. J Clin Oncol. 1992; 10: 1666-73. Google Scholar Author, Article, and Disclosure InformationAuthors: Raymond P. Warrell Jr., MD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOncology Pharmacotherapy: Clinical Applications of All-Trans-Retinoic Acid in Hematologic MalignanciesAcute Promyelocytic Leukemia 15 March 1993Volume 118, Issue 6Page: 472-473KeywordsChildrenCoagulopathyDrugsFeversLeukocytosisPulmonary diseasesRetinoic acidSafetySteroidsWeight gain ePublished: 15 August 2000 Issue Published: 15 March 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Xanthine oxidase inhibition does not limit canine infarct size.
Authors: S W Werns, C M Grum, A Ventura, R A Hahn, P P Ho, R D Towner, J C Fantone, M A Schork, B R Lucchesi
Journal: Circulation (1991)

Evidence supporting the role of xanthine oxidase in myocardial reperfusion injury is based on studies with pharmacological interventions used to inhibit enzyme function. Controversy exists, however, regarding the true role of xanthine oxidase in reperfusion injury. This study was performed to determine whether xanthine oxidase inhibition limits myocardial injury due to coronary artery occlusion and reperfusion.Anesthetized dogs underwent coronary artery occlusion (90 minutes) and reperfusion (6 hours). Oxypurinol (28 mg/kg) or amflutizole (30 mg/kg), chemically unrelated inhibitors of xanthine oxidase, or vehicle was infused intravenously 15 minutes before and 3 hours after reperfusion. Regional myocardial blood flow was determined with radiolabeled microspheres. Infarct size was determined with the tetrazolium method. Myocardial infarct size (percent of risk region) was less in oxypurinol-treated dogs, 32 +/- 16%, compared with that of the control group, 46 +/- 15%. Infarct size for the amflutizole-treated dogs, 40 +/- 21%, was not significantly different from that of the control group. There were no differences in rate-pressure product or collateral blood flow to account for differences in infarct size. Uric acid concentration in the coronary venous plasma increased after reperfusion in the dogs treated with vehicle but not in the drug-treated dogs. Xanthine oxidase inhibition was demonstrated in each of the drug treatment groups, but only oxypurinol limited the extent of myocardial injury.Previously reported cardioprotective effects of allopurinol, noted to occur only when the drug was administered chronically, may be related to a property of oxypurinol, a major metabolite of allopurinol. The beneficial effect of oxypurinol is unrelated to inhibition of superoxide formation during xanthine oxidase-catalyzed oxidation of xanthine and hypoxanthine.
Multi-disciplinary pre-therapeutic consultation significantly improves management of breast cancer patients.
Authors: N Ciobotariu, G Fioretta, E Rapiti, I Neyroud, S Balmer-Majno, A Sappino, P Schaefer, C Bouchardy, G Vlastos
Journal: Cancer Research (2009)

Abstract Abstract #6151 Introduction&amp;#x2028; Modern therapeutic management of breast cancer requires a multidisciplinary approach. Since 2001, the Geneva University Hospitals has set up a pre-therapeutic consultation (COSP) involving gynaecologists, medical oncologists, radiation therapists, as well as radiologists, pathologists, plastic surgeons, and nurses. The COSP team discusses and provides therapeutic recommendations for newly diagnosed breast cancer patients seen in our institution. This study evaluates the impact of COSP on patient's management.&amp;#x2028; Patients and methods&amp;#x2028; Between 2001-2005, 1771 patients had breast cancer diagnosis among the resident population: 750 patients were referred to the COSP and 1021 were not. We compared patients and tumours characteristics between these two groups by logistic regression. We compared concordance between initial proposed therapeutic option and final COSP treatment recommendation by heterogeneity test. Changes in treatment were considered as major if they concerned type of surgery, or the addition of systemic neo-adjuvant treatments. Other changes were coded as minor. Trend tests were calculated to evaluate management changes over time.&amp;#x2028; Results&amp;#x2028; Patients referred to the COSP were significantly younger, more often of low socio-economic status, foreigners, divorced, and treated in public sector. They were less frequently diagnosed through screening, and had more advanced stage at diagnosis. Complete initial treatment recommendation was available for 654 patients. For 109 (17%) patients, COSP dramatically changed the initial therapeutic propositions. For 169 (26%) patients, COSP proposed only minor changes. Among patients referred to the COSP, we observed a significant increase of immediate reconstructive surgery (p&amp;lt;0.001) and an increase of standard treatment options for women aged 80 years or more (p&amp;lt;0.001). Similar changes were absent among patients not referred to the COSP.&amp;#x2028; Conclusion&amp;#x2028; The multi-disciplinary pre-therapeutic consultation provides important changes in initial treatment options in routine health care practice. In particular it improves reconstruction and generalisation of good practices in elderly patients. This approach should become a gold-standard in the management of all breast cancer patients. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6151.
Endogenous Nitric Oxide Synthesis and Vascular Leakage in Ischemic-Reperfused Rabbit Lungs
Authors: HARTWIG SCHÜTTE, KONSTANTIN MAYER, HEIKO BURGER, MARTIN WITZENRATH, TOBIAS GESSLER, WERNER SEEGER, FRIEDRICH GRIMMINGER
Journal: American Journal of Respiratory and Critical Care Medicine (2001)

Pulmonary edema formation resulting from loss of capillary barrier properties is a prominent finding in lung ischemia/reperfusion (I/R) injury. The role of endogenous nitric oxide (NO) in this process is unresolved. We exposed buffer-perfused rabbit lungs to warm I/R and measured air space NO liberation and intravascular accumulation of NO degradation products. In lungs undergoing 210 min of ischemia with normoxic ventilation, with maintenance of positive intravascular pressure to avoid vascular collapse, NO synthesis was moderately reduced during ischemia but was fully restored upon reperfusion, and a moderate leakage response occurred during reperfusion. Pretreatment with the NO synthase inhibitor NG-monomethyl-l-arginine (l-NMMA) suppressed NO synthesis but did not affect the leakage. During ischemia with anoxic ventilation, NO synthesis was fully abrogated, but again promptly reappeared upon reperfusion and entrance of oxygen into the system. It was with this protocol that the most severe vascular leakage was encountered, which was markedly reduced in the presence of l-NMMA or superoxide dismutase. We conclude that endogenous NO does not play a major role in the induction or mitigation of I/R injury under conditions of normoxic ischemia, but that return of endogenous NO synthesis upon reperfusion after anoxic ischemia contributes substantially to the triggering of vascular leakage, possibly via interaction with superoxide.
Very-Low-Calorie Diets
Authors: Thomas J. Flynn
Journal: JAMA (1990)

To the Editor.—  The treatment of obesity is a matter of opinion, not of fact. The recent commentary by Wadden et al 1 recommends a responsible program of very-low-calorie diets plus behavioral therapy for those who are 30% overweight or more. Yet studies conducted by Dr Wadden and others working with the Sandoz Nutritional Company do not support this recommendation.  Wadden et al 2 compared three groups of patients: those treated by very-low-calorie diets alone, by behavioral therapy alone, and by a combination therapy such as that recommended in the commentary. At the three-year follow-up, however, subjects in all three conditions had regained between 74% and 85% of their end-of-treatment weight loss and differences in weight loss among conditions were no longer significantly different. 2 Dr Stunkard, 3 writing separately, recommended conservative treatments with behavioral therapy over such radical ones as jawwiring and very low calorie diets. Another study
The biological consequences of cutaneous laser surgery
Authors: E. Tanghetti
Journal: British Journal of Dermatology (2010)

Conflicts of interest None declared. ORIGINAL ARTICLE, p 757 Over the past 30 years enormous progress has been made in understanding the physics of light–tissue interactions. A sophisticated array of highly engineered products has followed closely behind these advances. Only recently have some of the biological consequences of these light–tissue interactions been studied in a sophisticated manner.1 In this month’s BJD, Orringer and colleagues2 have explored a number of techniques investigating some of the molecular consequences of nonablative laser treatments. They have also studied the important question of high and low fluence microbeam injury depths. Some authors have suggested that deeper depths of dermal injury produce better clinical outcomes.3 Others have questioned this assumption based on the remarkable clinical improvements noted with ablative laser resurfacing and the nice clinical outcomes noted with 1440‐nm nonablative treatments producing 200–300 μm of dermal injury. Our clinical and histological investigations have noted a brisk inflammatory response extending 2000 μm into the dermis with a 1440‐nm fractional device with good clinical outcomes.4 Laubach et al.,5 using a fractional 1550‐nm nonablative device, studied both superficial and deep wounding parameters with equal amounts of total energy. He and his colleagues noted similar clinical responses for acne scars with both settings.
Monitoring lithium treatment.
Authors: T. M. Egan, J. M. Grigor
Journal: BMJ (1992)

On admission hewas semiconscious and scored 9 on the Glasgow coma score.He showed writhing movements of his hands and subsequently had a short tonic-clonic fit.Both his plantar responses were extensor, but the remainder of the physical examination gave normal results.Initial investiga- tions showed a serum sodium concentration of 121 mmol/l, potassium 3 9 mmol/l, and chloride 90 mmol/l with a creatinine concentration of 54 [tmol/l and osmolarity of 254 mmol/l.A com-
Effects of Ketotifen and Clemastine on Passive Transfer of Reaginic Reaction
Authors: Kjell Aas
Journal: Allergy (1979)

Passive transfer (PK) tests were performed with a reaginic serum on a recipient reacting with an immediate and a more prolonged reaction when specifically challenged. Both reactions are thought to be mediated by IgE immunology. Ketotifen, a cycloheptathiophene derivative, and clemastine, given to the recipient in maximal clinical doses for 3 days, inhibited the immediate reaction. Ketotifen had a very slight effect also on the prolonged reaction. The results indicate that the in vivo effects of ketotifen in the human system are due not so much to mast cell inhibitory mechanisms, but more to post‐release antihistaminic and some anti‐inflammatory properties.
923 HEPARANASE ACCELERATES PROLIFERATION OF BOTH HEPATOCYTES AND SINUSOIDAL ENDOTHELIAL CELLS AFTER PARTIAL HEPATECTOMY DESPITE IL-6 AND TNF-A DOWN REGULATION
Authors: J. Carmel, A. Arish, N. Ilan, G. Shoshany, I. Vlodavsky, Y. Baruch
Journal: Journal of Hepatology (2010)
Spectral Fluorescence Molecular Imaging of Lung Metastases Targeting HER2/neu
Authors: Yoshinori Koyama, Yukihiro Hama, Yasuteru Urano, Dao M. Nguyen, Peter L. Choyke, Hisataka Kobayashi
Journal: Clinical Cancer Research (2007)

Abstract Purpose: Surgical resection of pulmonary metastases is now a clinically accepted cancer therapy but its success depends on the accurate localization and removal of all tumor foci. To enhance the detection of pulmonary metastases during surgery, we developed an i.v. administered optical probe that uses a monoclonal antibody, Herceptin (trastuzumab), conjugated to a fluorophore, rhodamine green (RhodG), to specifically detect human epidermal growth factor receptor type 2 (HER2/neu)–expressing pulmonary lesions in an animal model of lung metastases. Experimental Design: Pulmonary metastases were induced by i.v. injection of gene-transfected murine embryonic fibroblasts (3T3) cells in a murine model to produce a mixed population of HER2+ and HER2− tumors. To image these tumors, an anti-HER2 (Herceptin) or a control (HUT) complementarity-determining region–grafted antibody was conjugated to RhodG and injected i.v. into mice. Spectral fluorescence imaging was done after thoracotomy and images were correlated with gross and microscopic pathology to assess sensitivity and specificity. Results: HER2+ tumors injected with Herceptin-RhodG were more fluorescent than either HER2− tumors or HER2+ tumors injected with HUT-RhodG at all time points. The maximal fluorescence signal in HER2+ tumors injected with Herceptin-RhodG was observed at 1 day postinjection. The tumors fluoresced primarily at the rim and not their center, reflecting the binding-site barrier that is commonly seen with high-affinity antibodies. Conclusion: A HER2-targeted optical imaging probe shows the ability to specifically enhance HER2+ pulmonary metastases but not HER2− pulmonary metastases. The high sensitivity and specificity of this probe is encouraging for the development of antigen-targeted optical probes to assist in the resection of pulmonary metastases.
The Long-Term Effects of False-Positive Mammograms
Authors: Berta M. Geller, Richard Pinckney
Journal: Annals of Internal Medicine (2007)

Letters20 November 2007The Long-Term Effects of False-Positive MammogramsBerta M. Geller, EdD and Richard Pinckney, MD, MPHBerta M. Geller, EdDFrom the University of Vermont, Burlington, VT 05405.Search for more papers by this author and Richard Pinckney, MD, MPHFrom the University of Vermont, Burlington, VT 05405.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-10-200711200-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read Brewer and colleagues' systematic review (1) with great interest. False-positive mammography happens frequently in the United States, and it is important to understand the ramifications of these test results. However, we found the opening sentence of the article misleading: “Regular mammography has become part of routine health care in the developed world for women 40 years of age or older.” Most women in the developed world do not start breast cancer screening at age 40 years. To open the article with this statement adds to the confusion about what is recommended and practiced throughout the ...References1. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146:502-10. [PMID: 17404352] LinkGoogle Scholar2. Geller BM, Zapka J, Hofvind SS, Scharpantgen A, Giordano L, Ohuchi N, et al. Communicating with women about mammography. J Cancer Educ. 2007;22:25-31. [PMID: 17570805] CrossrefMedlineGoogle Scholar3. International Cancer Screening Network. Characteristics of Breast Cancer Screening Programs in 19 ICSN Countries Responding to a Survey in 2002. Accessed at appliedresearch.cancer.gov/icsn/breast/policies1.html on 21 September 2007. Google Scholar Author, Article, and Disclosure InformationAuthors: Berta M. Geller, EdD; Richard Pinckney, MD, MPHAffiliations: From the University of Vermont, Burlington, VT 05405.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: The Long-Term Effects of False-Positive Mammograms Noel T. Brewer , Talya Salz , and Sarah E. Lillie The Long-Term Effects of False-Positive Mammograms Noel Brewer , Talya Salz , and Sarah E. Lillie The Long-Term Effects of False-Positive Mammograms John Brodersen and Hanne Thorsen Metrics 20 November 2007Volume 147, Issue 10Page: 739KeywordsBreast cancer screeningConflicts of interestHealth careMammographySystematic reviews ePublished: 20 November 2007 Issue Published: 20 November 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
&lt;emph type="ital"&gt;Monet Painting in His Garden at Argenteuil&lt;/emph&gt;
Authors: Thomas B. Cole
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer specialist found guilty of misconduct
Authors: A. Tuffs
Journal: BMJ (2002)

A publication in Nature Medicine by the cancer specialist Alexander Kugler and 14 other authors from Gottingen, Tubingen, and Berlin does not fulfil the criteria of good clinical practice.

This is the verdict of a committee from Gottingen University, which was supported by four renowned external scientists.

In 2000 Kugler, then a senior registrar in the urology department of Gottingen University Hospital, had published a prizewinning clinical study claiming that kidney cancer can be treated effectively and safely with a vaccine …